REDMOD

By Mayo Clinic (internal research tool)
· USA
Mayo Clinic — Early pancreatic cancer detection.
Predictive
Oncology
Production
Not Formally Regulated
Regulatory status
Not Formally Regulated
Deployment
Production
Clinical role
Adjunct (decision support)
Headquarters
USA
AI type
Predictive

Precise indication

Early pancreatic cancer detection.

Regulatory status

Internal research tool, not commercially marked/cleared.

Clinical evidence

Vendor-supported

Not applicable (not commercially marketed).

Independent

Third-party industry report citing that the tool flagged 73% of pancreatic cancers at least 16 months before diagnosis — a research-stage finding, not yet a routine clinical deployment.

Real-world deployment

Research/validation stage at Mayo Clinic; not a generalizable commercial deployment.

Interoperability

European status

Editorial verdict

Limits and uncertainties

Still a research tool — do not present as ‘in production’ without clarifying this is investigational, internal use.

Sources

https://aiweekly.co/ai-use-cases/industry/healthcare

This profile is not medical advice or an endorsement. Hospitals should perform their own due diligence (regulatory compliance, GDPR, cybersecurity, integration, local clinical validation). How we evaluate

At a glance
Vendor
Mayo Clinic (internal research tool)
Headquarters
USA
AI type
Predictive
Specialty
Clinical role
Adjunct (decision support)
CE marking
Notified body
EU AI Act
Data hosting
Last verified
Reviewed by
How we evaluate

Every profile documents the precise indication, regulatory status, vendor-supported and independent evidence, real-world deployment, limits and dated sources.

A independent systematic review or prospective multicentre study · B at least one independent peer-reviewed study · C peer-reviewed, vendor-supported · D vendor claims only.

Read the methodology →

Spotted an error?

Vendors, authors and clinicians can request a correction. Corrections are dated on the profile.